Eli Lilly and Company (NYSE:LLY) Shares Sold by Claris Advisors LLC MO

Claris Advisors LLC MO decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 17.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 546 shares of the company’s stock after selling 119 shares during the quarter. Claris Advisors LLC MO’s holdings in Eli Lilly and Company were worth $422,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in LLY. Clare Market Investments LLC purchased a new position in Eli Lilly and Company in the fourth quarter worth approximately $1,703,000. Vista Investment Partners II LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth $8,848,000. Independent Advisor Alliance increased its holdings in Eli Lilly and Company by 11.1% in the fourth quarter. Independent Advisor Alliance now owns 43,968 shares of the company’s stock valued at $33,943,000 after buying an additional 4,385 shares during the last quarter. Altiora Financial Group LLC lifted its holdings in Eli Lilly and Company by 52.7% during the 4th quarter. Altiora Financial Group LLC now owns 974 shares of the company’s stock worth $752,000 after buying an additional 336 shares during the last quarter. Finally, Paragon Private Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 7.2% during the 4th quarter. Paragon Private Wealth Management LLC now owns 1,323 shares of the company’s stock worth $1,021,000 after acquiring an additional 89 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of several research analyst reports. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Citigroup cut their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Morgan Stanley set a $1,146.00 price target on Eli Lilly and Company in a research report on Thursday. Finally, Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a research note on Friday, January 17th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,009.72.

Eli Lilly and Company Stock Down 4.7 %

LLY stock opened at $828.80 on Tuesday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company’s 50-day moving average price is $827.73 and its 200 day moving average price is $846.36. Eli Lilly and Company has a 52 week low of $711.40 and a 52 week high of $972.53. The company has a market cap of $785.84 billion, a P/E ratio of 70.78, a P/E/G ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has authorized a share repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.